A vaccine created to prevent the recurrence of the deadly skin cancer melanoma is about twice as effective when patients also receive two components that boost the number and effectiveness of immune system cells called dendritic cells, according to phase 2 clinical trial results published in Nature Cancer in November. These results are important, according to researchers, because most cancer vaccine trials have failed to show clinical efficacy. These results show that adding two immune-boost...